Kalpana Chawla Government Medical College to start clinical trial of antibody cocktail

Karnal, June 2

The state has selected the Kalpana Chawla Government Medical College (KCGMC), a dedicated Covid facility for Karnal, Kurukshetra, Kaithal and Yamunanagar districts, to conduct the clinical trials of monoclonal antibody cocktail to treat patients with mild to moderate infection.

“We have received a communication from the Director, Medical Education, regarding the selection of the KCGMC for the human trial of monoclonal antibody cocktail on Covid patients with mild to moderate infection. We have made all arrangements for it. A dedicated place has been identified for the therapy on human volunteers. We will start the trial as soon as the ICMR issues the guidelines in this regard,” said Dr Jagdish Dureja, Director, KCGMC.

The therapy came into limelight after it was administered to US ex-president Donald Trump. Now, it is being administered in several corporate hospitals in India. “Following the results, the state has allowed its clinical trial on Covid patients,” he said, adding that the therapy was a cocktail of two monoclonal antibodies.

Dr Dureja claimed that it would reduce the chances of hospitalisation. “The antibody cocktail is priced at around Rs 60,000 per dose and a single dose is given.” “We are preparing a list of patients willing to get the therapy.” — TNS